Louis J Aronne

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi request reprint New targets for obesity pharmacotherapy
    L J Aronne
    Weill Medical College of Cornell University, New York, New York, USA
    Clin Pharmacol Ther 81:748-52. 2007
  2. ncbi request reprint Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy
    Louis J Aronne
    Weill Medical College of Cornell University, New York, New York 10021 7917, USA
    Am J Cardiol 100:18P-26P. 2007
  3. ncbi request reprint Therapeutic options for modifying cardiometabolic risk factors
    Louis J Aronne
    Weill Medical College of Cornell University, Columbia College of Physicians and Surgeons, and the Comprehensive Weight Control Program, New York Presbyterian Hospital, New York, New York 10021, USA
    Am J Med 120:S26-34. 2007
  4. doi request reprint When prevention fails: obesity treatment strategies
    Louis J Aronne
    Department of Medicine, Weill Cornell Medical College, and Comprehensive Weight Control Program, New York Presbyterian Hospital, New York, New York 10028, USA
    Am J Med 122:S24-32. 2009
  5. ncbi request reprint Gastric pacing is not enough: additional measures for an effective obesity treatment program
    Louis J Aronne
    Weill Cornell University Medical College, New York, NY, USA
    Obes Surg 14:S23-7. 2004
  6. doi request reprint A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
    L J Aronne
    Weill Cornell Medical College, New York, NY 10021 7917, USA
    Int J Obes (Lond) 34:919-35. 2010
  7. ncbi request reprint Overweight and obesity: key components of cardiometabolic risk
    Louis J Aronne
    Weill Medical College of Cornell University, New York, New York 10065, USA
    Clin Cornerstone 8:29-37. 2007
  8. ncbi request reprint Weight gain in the treatment of mood disorders
    Louis J Aronne
    Comprehensive Weight Control Program, Weill Medical College of Cornell University, New York, N Y, USA
    J Clin Psychiatry 64:22-9. 2003
  9. ncbi request reprint Obesity as a disease: etiology, treatment, and management considerations for the obese patient
    Louis J Aronne
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Obes Res 10:95S-96S. 2002
  10. ncbi request reprint Adiposity and fat distribution outcome measures: assessment and clinical implications
    Louis J Aronne
    Weill Medical College of Cornell University, 1165 York Avenue, New York, NY 10021, USA
    Obes Res 10:14S-21S. 2002

Detail Information

Publications35

  1. ncbi request reprint New targets for obesity pharmacotherapy
    L J Aronne
    Weill Medical College of Cornell University, New York, New York, USA
    Clin Pharmacol Ther 81:748-52. 2007
    ..New antiobesity therapies are in development that target anabolic or catabolic regulatory networks to reduce food intake and/or increase energy expenditure to promote weight loss...
  2. ncbi request reprint Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy
    Louis J Aronne
    Weill Medical College of Cornell University, New York, New York 10021 7917, USA
    Am J Cardiol 100:18P-26P. 2007
    ....
  3. ncbi request reprint Therapeutic options for modifying cardiometabolic risk factors
    Louis J Aronne
    Weill Medical College of Cornell University, Columbia College of Physicians and Surgeons, and the Comprehensive Weight Control Program, New York Presbyterian Hospital, New York, New York 10021, USA
    Am J Med 120:S26-34. 2007
    ....
  4. doi request reprint When prevention fails: obesity treatment strategies
    Louis J Aronne
    Department of Medicine, Weill Cornell Medical College, and Comprehensive Weight Control Program, New York Presbyterian Hospital, New York, New York 10028, USA
    Am J Med 122:S24-32. 2009
    ..Studies are underway to identify new therapeutic strategies to effectively reduce weight, as well as to provide long-term data on successful weight loss maintenance strategies...
  5. ncbi request reprint Gastric pacing is not enough: additional measures for an effective obesity treatment program
    Louis J Aronne
    Weill Cornell University Medical College, New York, NY, USA
    Obes Surg 14:S23-7. 2004
    ..Thus, gastric stimulation should work best when combined with other treatments such as diet, exercise, and behavioral change...
  6. doi request reprint A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
    L J Aronne
    Weill Cornell Medical College, New York, NY 10021 7917, USA
    Int J Obes (Lond) 34:919-35. 2010
    ..To evaluate the efficacy, safety and tolerability of taranabant in obese and overweight patients.Design:Double-blind, randomized, placebo-controlled study...
  7. ncbi request reprint Overweight and obesity: key components of cardiometabolic risk
    Louis J Aronne
    Weill Medical College of Cornell University, New York, New York 10065, USA
    Clin Cornerstone 8:29-37. 2007
    ..While there are few medical options currently available, new compounds for the treatment of obesity are under investigation...
  8. ncbi request reprint Weight gain in the treatment of mood disorders
    Louis J Aronne
    Comprehensive Weight Control Program, Weill Medical College of Cornell University, New York, N Y, USA
    J Clin Psychiatry 64:22-9. 2003
    ..This article provides an overview of the weight-gain potential of several classes of drugs commonly used in psychiatric practice and considerations for clinicians in prescribing these medications...
  9. ncbi request reprint Obesity as a disease: etiology, treatment, and management considerations for the obese patient
    Louis J Aronne
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Obes Res 10:95S-96S. 2002
  10. ncbi request reprint Adiposity and fat distribution outcome measures: assessment and clinical implications
    Louis J Aronne
    Weill Medical College of Cornell University, 1165 York Avenue, New York, NY 10021, USA
    Obes Res 10:14S-21S. 2002
  11. ncbi request reprint The endocannabinoid system as a target for obesity treatment
    Louis J Aronne
    Weill Cornell Medical College, New York, New York, USA
    Clin Cornerstone 9:52-64; discussion 65-6. 2008
    ..Thus, these agents may provide a rational and effective approach for the management of not only overweight and obesity but also their metabolic and cardiovascular sequelae...
  12. ncbi request reprint Pharmacotherapy for obesity
    Lisa M Neff
    Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, Rockefeller University Hospital, 1230 York Avenue, Box 332, New York, NY 10021, USA
    Curr Atheroscler Rep 9:454-62. 2007
    ..Important drug targets that are highlighted in this review include adipocyte-derived hormones, hypothalamic neuropeptides, and gastrointestinal hormones...
  13. ncbi request reprint Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial
    F Xavier Pi-Sunyer
    Obesity Research Center, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY 10025, USA
    JAMA 295:761-75. 2006
    ..Rimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese...
  14. ncbi request reprint Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction
    Michelle Lee
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Am J Cardiol 99:68B-79B. 2007
    ..Such global risk reduction is crucial for patients with diabetes, in whom CAD is a major cause of mortality...
  15. ncbi request reprint Rimonabant: new data and emerging experience
    Suzanne M Wright
    Comprehensive Weight Control Program, New York Presbyterian Hospital, Weill Medical College of Cornell University, 1165 York Avenue, New York, NY 10065, USA
    Curr Atheroscler Rep 10:71-8. 2008
    ..The use of endocannabinoid antagonists such as rimonabant provides a promising therapeutic approach to the treatment of obesity and its associated cardiometabolic risks...
  16. ncbi request reprint Obesity as a disease state: a new paradigm for diagnosis and treatment
    Louis J Aronne
    Weill Cornell Medical College, New York, New York, USA
    Clin Cornerstone 9:9-25; discussion 26-9. 2009
    ..Several weight loss drugs are available for long-term use, with others in various stages of clinical development...
  17. doi request reprint The challenge of treating obesity: the endocannabinoid system as a potential target
    Kathy Keenan Isoldi
    Clinical Nutrition Services, The Comprehensive Weight Control Program, New York, NY, USA
    J Am Diet Assoc 108:823-31. 2008
    ..Emerging research data reveals pathways that influence appetite and energy metabolism, and this knowledge may form the foundation for new clinical treatment options for obese individuals...
  18. doi request reprint Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus
    Leon I Igel
    Department of Medicine, New York Presbyterian Weill Cornell Medical Center, 505 E 70th Street, Suite 450, New York, NY 10021, USA
    Curr Atheroscler Rep 14:60-9. 2012
    ..Emphasis is also placed on a proposed paradigm shift from the glucose-centric to the weight-centric management of type 2 diabetes mellitus...
  19. doi request reprint Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial
    Louis J Aronne
    Weill Cornell Medical College, New York, New York, USA
    Obesity (Silver Spring) 18:1739-46. 2010
    ..However, the majority of subjects receiving these treatments remained within normal blood pressure ranges. These results support the potential of pramlintide-containing combination treatments for obesity...
  20. ncbi request reprint Obesity and pharmacologic therapy
    Marie Thearle
    Department of Preventive Medicine, Columbia University College of Physicians and Surgeons, Russ Berrie Medical Science Pavilion, 1150 St Nicholas Avenue, Room 238, New York, NY 10032, USA
    Endocrinol Metab Clin North Am 32:1005-24. 2003
    ..This weight loss is associated with improvements in blood pressure, insulin sensitivity, and dyslipidemia. Multiple new therapies that target several different regulatory pathways are currently in clinical trials...
  21. ncbi request reprint Classification of obesity and assessment of obesity-related health risks
    Louis J Aronne
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    Obes Res 10:105S-115S. 2002
    ..Gathering this information will allow the clinician to tailor a weight-loss program to each patient individually. Although this represents the most challenging component of obesity care, resources are available to guide the clinician...
  22. pmc Randomized double-blind placebo-controlled study of leptin administration after gastric bypass
    Judith Korner
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Obesity (Silver Spring) 21:951-6. 2013
    ..The main objective of this study was to determine whether leptin administration to post-RYGB patients would promote further weight reduction...
  23. doi request reprint Implantable gastric stimulator does not prevent the increase in plasma ghrelin levels that occurs with weight loss
    Judith Korner
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Obesity (Silver Spring) 19:1935-9. 2011
    ..Further studies are needed to determine whether changes in technology can improve weight loss and maintenance, perhaps using gut hormones as biomarkers of possible efficacy...
  24. ncbi request reprint Managing overweight and obesity in women
    Jana Klauer
    Comprehensive Weight Control Program, New York, New York 10021, USA
    Clin Obstet Gynecol 45:1080-8. 2002
  25. ncbi request reprint Pharmacological approaches to weight reduction: therapeutic targets
    Judith Korner
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Clin Endocrinol Metab 89:2616-21. 2004
  26. ncbi request reprint The impact of obesity on cardiometabolic risk
    Louis J Aronne
    New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY, USA
    JAAPA . 2007
  27. ncbi request reprint Causes of obesity
    Suzanne M Wright
    Comprehensive Weight Control Program, Weill Cornell Medical College New York Presbyterian Hospital, 1165 York Avenue, New York, NY 10065, USA
    Abdom Imaging 37:730-2. 2012
    ..The dramatic rise in obesity has also occurred in many other countries, and the causes of this increase are not fully understood (Hill and Melanson, Med Sci Sports Exerc 31:S515-S521, 1999)...
  28. pmc The emerging science of body weight regulation and its impact on obesity treatment
    Judith Korner
    Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Clin Invest 111:565-70. 2003
  29. doi request reprint Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance
    Louis J Aronne
    Weill Cornell Medical College, Cornell University, New York, New York, USA
    Obesity (Silver Spring) 19:1404-14. 2011
    ..However, the reported increases in psychiatric symptoms were not consistently dose dependent...
  30. ncbi request reprint Cardiovascular disease in obesity: A review of related risk factors and risk-reduction strategies
    Louis J Aronne
    Weill Cornell Medical College of Cornell University, New York, NY The Comprehensive Weight Control Program, 1165 York Avenue, New York, NY 10028
    J Clin Lipidol 1:575-82. 2007
    ..The endocannabinoid system is now recognized as a potentially viable pathway to modulate appetite and energy, lipid, and glucose metabolism...
  31. doi request reprint Emerging pharmacotherapy for obesity
    Louis J Aronne
    Comprehensive Weight Control Program, Weill Cornell Medical College, NY 10065, USA
    Expert Opin Emerg Drugs 16:587-96. 2011
    ..Obesity is a rapidly increasing global health problem. The rates of obesity have tripled over the past three decades and are predicted to rise even further. The need for safe and effective therapies is great and has gone unmet...
  32. pmc Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity
    Steve R Smith
    Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA
    Diabetes Care 31:1816-23. 2008
    ..To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI)...
  33. ncbi request reprint Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients
    James L Early
    Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, 1010 N Kansas Rd, Wichita, KS 67214 3199, USA
    Obesity (Silver Spring) 15:1464-72. 2007
    ..Our objective was to assess the efficacy and safety of sibutramine with a low-calorie diet (LCD) and commercial meal-replacement product in achieving weight loss and weight-loss maintenance in obese patients...
  34. ncbi request reprint Medical assessment of obese older patients
    Annamaria Calleo-Cross
    Westchester Medical Group, 3020 Westchester Avenue, Purchase, NY 10577, USA
    Clin Geriatr Med 21:689-99, v. 2005
    ..In the older patient, building lean body mass with resistance training seems to be of primary importance. A low-glycemic diet composed of healthy foods is recommended...
  35. ncbi request reprint Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group IV: prevention/treatment
    Rebecca M Mullis
    Circulation 110:e484-8. 2004